Liver Cancer

Younger and female patients with a variety of cancer types tend to have strong immune systems that naturally fight an array of cancer cells. The tumor cells the immune system doesn’t destroy are the most evasive, both to the immune system and medications that boost its activity, and this makes checkpoint inhibitor immunotherapy less effective in this population.

At a median follow-up of 10 months, all patients who received Tafinlar plus Mekinist achieved an overall response rate of 51%.

Could paradigm shifts in cancer research help find a cure for cholangiocarcinoma? Experts discuss.

After lifesaving medicine became available to treat hepatitis C virus, a risk factor for liver cancer, racial inequities in the death rate from the malignancy began a steady upward climb.

The results of an ongoing study designed to reveal genetic characteristics linked with the development of cholangiocarcinoma could pave the way for more accurate prognoses, as well as new treatments.

A survey administered by pharmaceutical company Incyte and the nonprofit Cholangiocarcinoma Foundation found that patients with bile duct cancer face more than a dozen symptoms or treatment-related side effects that negatively affect their daily lives.

After losing the sister she raised to an aggressive type of liver cancer, one woman has devoted herself to stamping out the disease.

U.S. Supreme Court Justice Ruth Bader Ginsburg, 87, has announced that she is currently undergoing chemotherapy for a cancer recurrence.

On the importance of finding more potent and well-tolerated therapies in hepatocellular carcinoma, Dr. Bruno Sangro explains: “The wider the spectrum of choices, the better we will be able to treat our patients.”

When it comes to hepatocellular carcinoma (HCC), doctors have a handful of treatment options at their disposal. But how do they decide what’s best?

A caregiver sheds light on the trials and tribulations of his wife's cancer journey and describes his awe in watching his wife's strength.

The Food and Drug Administration approved the combination of Tecentriq and Avastin in patients with unresectable or metastatic hepatocellular carcinoma, making it the first immunotherapy regimen to be approved for this cancer type.

In the spring 2020 issue of CURE®, Editor-in-Chief Dr. Debu Tripathy details how preventing liver cancer starts with understanding the precursors to cancer’s development.

Nonalcoholic fatty liver disease can lead to cancer. Patients can reverse the damage through diet and exercise, but how can they know if they have the common condition?

The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.

A gastrointestinal malignancy expert discusses the role genomics play in cholangiocarcinoma, as well as how genetic profiling may identify which treatment is best for patients.

The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.

Although the new coronavirus has led to a delay in some cholangiocarcinoma trials, experts don’t expect the trials to come to an end.

The Food and Drug Administration approved the dual immunotherapy of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma. Here’s what you need to know.

The Food and Drug Administration granted an accelerated approval to the combination of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with Nexavar.

Researchers hope the new PROOF trial will show that infigratinib, a targeted drug, will expand options in treating advanced cholangiocarcinoma. Patients are enrolling now.

A circulating cell-free DNA test for patients with gastrointestinal cancers has a 90% accuracy rate to detect patients’ cancers and could provide a standard test in the future, according to new study findings.

The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.